Single-molecule simultaneous profiling of DNA methylation and DNA-protein interactions with Nanopore-DamID

Contribution of UPF1 and RCOR1 to androgen response of prostate cancer cells.

Bisphenol A enhances retinoic acid-HOX genes signaling disrupting brain development: human

mRNA-seq of human adipose tissue-derived mesenchymal stem/stromal cells (MSCs)

Megacomplex protects ESR1 from degradation by Fulvestrant in epithelial ovarian cancer

Integrative miRNOMe profiling reveals the miR-195-5p-CHEK1 axis and its impact on luminal breast cancer outcomes

A novel model for high-grade transformation in IDH mutant glioma (Methylation Analysis)

MicroRNA expression profling from 14 adult whole blood samples with flow cytometry cell fractions

Impact of BCL2 Overexpression in castration resistance prostate cancer progression I

Impact of androgen stimulation on BCL2 Overexpressed LNCaP cells

Impact of BCL2 inhibitor Venetoclax on LNCaP cells

Epigenetic modulation of γ-globin expression as a new therapeutic approach for sickle cell disease

Multi-omics analyses construct an inflammatory response based prognostic gene signature for cervical cancer and suggest tumor infiltrating monocytes subgroups as key players

Transcriptomic Profiling of TNFα-Stimulated Human Umbilical Vein Endothelial Cells (HUVECs) With and Without Isoginkgetin (ISOGK) Pretreatment.

Patient-derived kidney organoids recapitulate ADPKD and enable the identification of RHO signaling inhibitors as candidate therapeutics

Study on the Mechanism of Exosome circAP2B1 Promoting Proliferation and Metastasis of Esophageal Squamous cell carcinoma

Patient-derived kidney organoids recapitulate ADPKD and enable the identification of RHO signaling inhibitors as candidate therapeutics [RNA-Seq]

Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch [Human DRG]

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma [PDX]

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma